Showing results (111-120 of 163) with videos related to

Sort By:
Pageof 17
Immunotargets and Therapy|March 25, 2026
Emerging Predictive Biomarkers of Immunotherapy Sensitivity in Patients with Non-Small Cell Lung CancerEleonora Gariazzo, Francesca Colamartini, Martina Ubaldi, et al.
Expert Opinion on Investigational Drugs|June 28, 2007
Aromatase inhibitors in post-menopausal metastatic breast carcinomaPaolo Carlini, Emilio Bria, Diana Giannarelli, et al.
Frontiers in Oncology|December 1, 2022
KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life populationSara Fancelli, Enrico Caliman, Francesca Mazzoni, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2024
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancerEnriqueta Felip, Giulio Metro, Daniel S W Tan, et al.
JTO Clinical and Research Reports|November 24, 2025
Crizotinib in Patients With <i>ROS1</i>-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS TrialLorenza Landi, Rita Chiari, Marcello Tiseo, et al.
Lung Cancer (Amsterdam, Netherlands)|December 19, 2024
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016Francesco Gelsomino, Luca Boni, Marcello Tiseo, et al.
Acta Neuropathologica Communications|August 27, 2020
New somatic TERT promoter variants enhance the Telomerase activity in GlioblastomaTiziana Pierini, Carlotta Nardelli, Anair Graciela Lema Fernandez, et al.
Future Oncology (London, England)|November 15, 2017
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerGiulio Metro, Antonio Passaro, Giuseppe Lo Russo, et al.
Lung Cancer (Amsterdam, Netherlands)|January 2, 2021
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b studyFilippo de Marinis, Konstantin K Laktionov, Artem Poltoratskiy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP RegistryArianna Marinello, Julia K Rotow, Meghanne Lomibao, et al.
Pageof 17